|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLMO2 |
Gene summary for SLMO2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLMO2 | Gene ID | 51012 |
| Gene name | PRELI domain containing 3B | |
| Gene Alias | C20orf45 | |
| Cytomap | 20q13.32 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9Y3B1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51012 | SLMO2 | P1_S1_AK | Human | Skin | AK | 4.59e-09 | -2.08e-01 | -0.3399 |
| 51012 | SLMO2 | P2_S3_AK | Human | Skin | AK | 2.11e-09 | -2.08e-01 | -0.3287 |
| 51012 | SLMO2 | P2_S4_SCCIS | Human | Skin | SCCIS | 4.65e-08 | -2.08e-01 | -0.3043 |
| 51012 | SLMO2 | P3_S6_AK | Human | Skin | AK | 2.11e-09 | -2.08e-01 | -0.3256 |
| 51012 | SLMO2 | P5_S10_cSCC | Human | Skin | cSCC | 9.71e-10 | -2.08e-01 | -0.299 |
| 51012 | SLMO2 | P1_cSCC | Human | Skin | cSCC | 2.56e-19 | 7.03e-01 | 0.0292 |
| 51012 | SLMO2 | P2_cSCC | Human | Skin | cSCC | 1.26e-15 | 5.15e-01 | -0.024 |
| 51012 | SLMO2 | P4_cSCC | Human | Skin | cSCC | 4.76e-14 | 5.44e-01 | -0.00290000000000005 |
| 51012 | SLMO2 | P10_cSCC | Human | Skin | cSCC | 3.09e-29 | 9.70e-01 | 0.1017 |
| 51012 | SLMO2 | cSCC_p1 | Human | Skin | cSCC | 2.11e-09 | -2.08e-01 | -0.1916 |
| 51012 | SLMO2 | cSCC_p10 | Human | Skin | cSCC | 2.11e-09 | -2.08e-01 | -0.2095 |
| 51012 | SLMO2 | cSCC_p11 | Human | Skin | cSCC | 2.11e-09 | -2.08e-01 | -0.2102 |
| 51012 | SLMO2 | cSCC_p3 | Human | Skin | cSCC | 2.11e-09 | -2.08e-01 | -0.2085 |
| 51012 | SLMO2 | cSCC_p4 | Human | Skin | cSCC | 9.96e-07 | -2.08e-01 | -0.2022 |
| 51012 | SLMO2 | cSCC_p6 | Human | Skin | cSCC | 4.59e-09 | -2.08e-01 | -0.1989 |
| 51012 | SLMO2 | cSCC_p7 | Human | Skin | cSCC | 9.96e-07 | -2.08e-01 | -0.2332 |
| 51012 | SLMO2 | cSCC_p8 | Human | Skin | cSCC | 2.11e-09 | -2.08e-01 | -0.1971 |
| 51012 | SLMO2 | cSCC_p9 | Human | Skin | cSCC | 9.71e-10 | -2.08e-01 | -0.1991 |
| 51012 | SLMO2 | NAG_1 | Human | Stomach | CSG | 1.10e-21 | 6.84e-01 | -0.3534 |
| 51012 | SLMO2 | NAG_2 | Human | Stomach | CSG | 5.35e-16 | 5.76e-01 | -0.3324 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |